Proposal for a multifactorial prognostic score that accurately classifies 3 groups of gastric carcinoma patients with different outcomes after neoadjuvant chemotherapy and surgery

Annals of Surgery

Volumn 256, Issue 6, 2012, Pages 1002-1007

  Becker, Karen ^a   Reim, Daniel ^a   Novotny, Alexander ^a   Zum Büschenfelde, Christian Meyer ^a   Engel, Jutta ^b   Friess, Helmut ^a   Höfler, Heinz ^a,c   Langer, Rupert ^d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

chemotherapy; gastric cancer; histopathology; prognosis score

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; PACLITAXEL;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER INVASION; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INDEPENDENT VARIABLE; LYMPH VESSEL; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; STOMACH CANCER; STOMACH CARCINOMA;

ADOLESCENT; ADULT; AGED; CARCINOMA; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; YOUNG ADULT;

EID: 84870064288     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318262a591     Document Type: Article

References (43)

1. Brenner B, Shah MA, Karpeh MS, et al. A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer. Ann Oncol. 2006;17:1404-1411.
2. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11-20.
3. Fujitani K, Ajani JA, Crane CH, et al. Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction. Ann Surg Oncol. 2007;14:1305-1311.
4. Li W, Qin J, Sun YH, et al. Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. World J Gastroenterol. 2010;16:5621-5628.
5. Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European organisation for research and treatment of cancer randomized trial 40954. J Clin Oncol. 2010;28:5210-5218.
6. Wu AW, Xu GW, Wang HY, et al. Neoadjuvant chemotherapy versus none for resectable gastric cancer. Cochrane Database Syst Rev. 2007;CD005047.
7. Okines A, Verheij M, Allum W, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21: v50-v54.
8. Becker K, Langer R, Reim D, et al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg. 2011;253:934-939.
9. Lordick F, Stein HJ, Peschel C, et al. Neoadjuvant therapy for oesophagogastric cancer. Br J Surg. 2004;91:540-551.
10. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. 6th ed. Berlin, Germany: Springer; 2009.
11. Sobin L, Gospodarowicz ML, Wittekind Ch. TNM Classification of Malignant Tumors. New York, NY: John Wiley & Sons; 2010.
12. Dicken BJ, Bigam DL, Cass C, et al. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg. 2005;241:27-39.
13. Dicken BJ, Saunders LD, Jhangri GS, et al. Gastric cancer: establishing predictors of biologic behavior with use of population-based data. Ann Surg Oncol. 2004;11:629-635.
14. Lagarde SM, ten Kate FJW, Reitsma JB, et al. Prognostic factors in ade-nocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol. 2006;24:4347-4355.
15. Siewert JR, Bottcher K, Stein HJ, et al. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 1998;228:449-461.
16. Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98:1521-1530.
17. Ott K, Sendler A, Becker K, et al. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer. 2003;6:159-167.
18. Gertler R, Stein HJ, Langer R, et al. Long-term outcome of 2920 patients with cancers of the esophagus and esophagogastric junction: evaluation of the New Union Internationale Contre le Cancer/American Joint Cancer Committee staging system. Ann Surg. 2011;253:689-698.
19. Ahn HS, Lee H-J, Hahn S, et al. Evaluation of the Seventh American Joint Committee on Cancer/International Union Against Cancer Classification of gastric adenocarcinoma in comparison with the sixth classification. Cancer. 2010;116:5592-5598.
20. Rausei S, Dionigi G, Boni L, et al. How does the 7th TNM edition fit in gastric cancer management? Ann Surg Oncol. 2011;18:1219-1221.
21. Rice TW, Rusch VW, Ishwaran H, et al. Cancer of the esophagus and esopha-gogastric junction. Cancer. 2010;116:3763-3773.
22. Wang W, Sun XW, Li CF, et al. Comparison of the 6th and 7th editions of the UICC TNM staging system for gastric cancer: results of a Chinese singleinstitution study of 1, 503 patients. Ann Surg Oncol. 2011;18:1060-1067.
23. Rödel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23:8688-8696.
24. Berger AC, Farma J, Scott WJ, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005;23:4330-4337.
25. Schneider PM, Baldus SE, Metzger R, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg. 2005;242:684-692.
26. Rizk NP, Venkatraman E, Bains MS, et al. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol. 2007;25:507-512.
27. Barbour AP, Jones M, Gonen M, et al. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response. Ann Surg Oncol. 2008;15:2894-2902.
28. Swisher SG, Hofstetter W, Wu TT, et al. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg. 2005;241:810-817; discussion 817-820.
29. Brucher BL, Becker K, Lordick F, et al. The clinical impact of histopatho-logic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer. 2006;106:2119-2127.
30. Langer R, Ott K, Feith M, et al. Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarci-nomas. Mod Pathol. 2009;22:1555-1563.
31. Rosenberg R, Nekarda H, Zimmermann F, et al. Histopathological response after preoperative radiochemotherapy in rectal carcinoma is associated with improved overall survival. J Surg Oncol. 2008;97:8-13.
32. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810-1820.
33. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroe-sophageal junction. N Engl J Med. 2001;345:725-730.
34. Ychou M, Boige V, Pignon J-P, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: a FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715-1721.
35. Di Costanzo F, Gasperoni S, Manzione L, et al. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst. 2008;100:388-398.
36. Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303:1729-1737.
37. Gallego-Plazas J, Menarguez-Pina F, Martinez-Banaclocha N, et al. Early distant relapse after optimal local control in locally advanced rectal cancer. Int Semin Surg Oncol. 2008;5:18.
38. Sun W, Metz J, Gallagher M, et al. Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarci-nomas. Cancer Chemother Pharmacol. 2011;67:621-627.
39. Chang AT, Ng WT, Law AL, et al. Adjuvant chemoradiation for resected gastric cancer: a 10-year experience. Gastric Cancer. 2011;14:63-71.
40. Gunderson LL, Callister MD, Jaroszewski DE, et al. Localized gastric or gastroesophageal cancer-chemoradiation is a pertinent component of adjuvant treatment for patients at high risk of relapse. Gastrointest Cancer Res. 2009;3:S26-S32.
41. Xiong HQ, Gunderson LL, Yao J, et al. Chemoradiation for resectable gastric cancer. Lancet Oncol. 2003;4:498-505.
42. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroe-sophageal junction. N Engl J Med. 2001;345:725-730.
43. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-697.